A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 08 Mar 2017 Planned number of patients changed from 30 to 15.
- 08 Mar 2017 Planned End Date changed from 1 Aug 2017 to 1 Jun 2018.
- 08 Mar 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2018.